Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Ian

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Science Signaling|December 17, 2009
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapyDeliang Guo, Robert M Prins, Julie Dang, et al.
Journal of Neuro-Oncology|November 11, 2021
Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825Nirav Patil, Eashwar Somasundaram, Kristin A Waite, et al.
Cancer Discovery|November 8, 2011
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathwayDeliang Guo, Felicia Reinitz, Mary Youssef, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Neuro-Oncology|June 4, 2011
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsAndrew B Lassman, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|June 5, 2012
Initial treatment patterns over time for anaplastic oligodendroglial tumorsKatherine S Panageas, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|July 6, 2014
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumorsKatherine S Panageas, Anne S Reiner, Fabio M Iwamoto, et al.
Neurosurgery|March 11, 2021
Sport-Related Structural Brain Injury and Return to Play: Systematic Review and Expert InsightScott L Zuckerman, Aaron M Yengo-Kahn, Alan R Tang, et al.
Cancer Discovery|May 17, 2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsIgor Vivanco, H Ian Robins, Daniel Rohle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort AnalysisVijay Ramaswamy, Thomas Hielscher, Stephen C Mack, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Science Signaling|December 17, 2009
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapyDeliang Guo, Robert M Prins, Julie Dang, et al.
Journal of Neuro-Oncology|November 11, 2021
Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825Nirav Patil, Eashwar Somasundaram, Kristin A Waite, et al.
Cancer Discovery|November 8, 2011
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathwayDeliang Guo, Felicia Reinitz, Mary Youssef, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Neuro-Oncology|June 4, 2011
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsAndrew B Lassman, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|June 5, 2012
Initial treatment patterns over time for anaplastic oligodendroglial tumorsKatherine S Panageas, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|July 6, 2014
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumorsKatherine S Panageas, Anne S Reiner, Fabio M Iwamoto, et al.
Neurosurgery|March 11, 2021
Sport-Related Structural Brain Injury and Return to Play: Systematic Review and Expert InsightScott L Zuckerman, Aaron M Yengo-Kahn, Alan R Tang, et al.
Cancer Discovery|May 17, 2012
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitorsIgor Vivanco, H Ian Robins, Daniel Rohle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort AnalysisVijay Ramaswamy, Thomas Hielscher, Stephen C Mack, et al.
Pageof 12